Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1998

View Archived Issues

Pharmacological profile of new alkylating agent from Menarini

Company Profile: Ribozyme

Company Profile: Onyx

FDA advisory panel recommends Apligraf

Synthelabo claims mixed and specific dopamine receptor ligands

New analgesic agents from Gruenenthal

Heterocyclic bradykinin antagonists in development at Hoechst Marion Roussel

BASF presents new ET antagonists

Newly identified human natural killer cell-activating factor reported by HGS

Yeda patents IFN-alpha/beta receptor-neutralizing antibodies

EPO peptides and anti-EPO antibodies from Behringwerke

Anti-ErbB3 antibodies described by Genentech in patent literature

Lactoferrin use in heparin neutralization described

Anxiolytic candidate with favorable pharmacokinetic properties developed at Warner-Lambert

Trovan soon to be available in pharmacies

Androtab-SL NDA is inadequate for approval, FDA says

PB-005 studied in postsurgical wound healing

Second-generation DHEA derivative in development at Pharmadigm

Potent antiretroviral activity shown for abacavir + protease inhibitor in HIV-positive patients

Shaman suspends phase II trial of Virend

Tasmar cleared by FDA

Promising efficacy reported at AIDS conference for amprenavir combinations

Crescendo and Alza to collaborate on chronic pain product

TheraTech and SmithKline Beecham join forces on nicotine product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...